NBC Securities Inc. Takes $337,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

NBC Securities Inc. bought a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,600 shares of the company's stock, valued at approximately $337,000.

Several other institutional investors also recently made changes to their positions in TWST. Versant Capital Management Inc grew its holdings in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $43,000. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $58,000. Finally, US Bancorp DE grew its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP Paula Green sold 1,101 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the sale, the senior vice president now owns 129,380 shares in the company, valued at approximately $4,871,157. This represents a 0.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 936 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the sale, the chief financial officer now owns 106,018 shares of the company's stock, valued at $3,154,035.50. This trade represents a 0.88% decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,012 shares of company stock worth $817,752 over the last ninety days. Company insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on TWST shares. The Goldman Sachs Group reduced their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Barclays reduced their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Stock Performance

TWST opened at $31.57 on Friday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -9.34 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90. The business has a 50 day moving average price of $34.33 and a two-hundred day moving average price of $41.95.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.